Nuclear medicine imaging methods of radiation-induced cardiotoxicity

E, Polomski; Antoni, M. Louisa; Jukema, J. Wouter; Kroep, Judith R.; Dibbets‐Schneider, Petra; Sattler, M.

doi:10.1053/j.semnuclmed.2022.02.001

Cited by 9 publications

(4 citation statements)

References 123 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The need for a lifelong surveillance in CSs treated by chest RT is well recognized, including in the recently released ESC guidelines, which recommend an annual CV risk assessment that includes ECG, measurement of NP levels and an assessment of CVRFs, echocardiography in asymptomatic high-risk adult CSs starting 5 years after RT (delivered to a volume that included the heart) and every 5 years thereafter, and non-invasive screening for CAD every 5–10 years in asymptomatic patients who received 15 Gy of median heart dose, starting 5 years after radiation ( 29 ). Screening for CAD may consist of physical or pharmacological stress tests, CT scan with assessment of the calcium score, coronary CT, or even coronary angiography ( 104 – 106 ). Of these, the calcium score and coronary CT have been used in many studies ( 105 , 106 ).…”

Section: Management Of Cancer Patients Treated With Chest Radiotherapymentioning

confidence: 99%

Cancer survivorship at heart: a multidisciplinary cardio-oncology roadmap for healthcare professionals

Bisceglia,

Canale,

Silvestris

et al. 2023

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

In cancer, a patient is considered a survivor from the time of initial diagnosis until the end of life. With improvements in early diagnosis and treatment, the number of cancer survivors (CS) has grown considerably and includes: (1) Patients cured and free from cancer who may be at risk of late-onset cancer therapy-related cardiovascular toxicity (CTR-CVT); (2) Patients with long-term control of not-curable cancers in whom CTR-CVT may need to be addressed. This paper highlights the importance of the cancer care continuum, of a patient-centered approach and of a prevention-oriented policy. The ultimate goal is a personalized care of CS, achievable only through a multidisciplinary-guided survivorship care plan, one that replaces the fragmented management of current healthcare systems. Collaboration between oncologists and cardiologists is the pillar of a framework in which primary care providers and other specialists must be engaged and in which familial, social and environmental factors are also taken into account.

show abstract

Section: Management Of Cancer Patients Treated With Chest Radiotherapymentioning

confidence: 99%

Cancer survivorship at heart: a multidisciplinary cardio-oncology roadmap for healthcare professionals

Bisceglia,

Canale,

Silvestris

et al. 2023

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

show abstract

“…Nuclear medicine imaging and particularly multigated acquisition (MUGA) scintigraphy have historically been at the frontline of LV monitoring in oncological patients. 40 , 41 Although challenged by CMR, 42 nuclear cardiology provides critical information for diagnosing, monitoring, and risk-stratifying cancer patients 15 , 16 , 43 – 45 ( Table 2 ). In the following part, we will review how nuclear cardiology can detect cardiac complications in oncological patients and discuss its role alongside echocardiography and CMR.…”

Section: Role Of Imaging For the Early Detection Of Cvd In Cancer Pat...mentioning

confidence: 99%

Tales from the future—nuclear cardio-oncology, from prediction to diagnosis and monitoring

Mikaïl

Chequer

Impériale

et al. 2023

European Heart Journal - Cardiovascular Imaging

View full text Add to dashboard Cite

Cancer and cardiovascular disease often share common risk factors, and patients with cardiovascular disease who develop cancer are at high risk of experiencing major adverse cardiac events. Additionally, cancer treatment can induce short- and long-term adverse cardiovascular events. Given the improvement in oncological patients’ prognosis, the burden in this vulnerable population is slowly shifting towards increased cardiovascular mortality. Consequently, the field of cardio-oncology is steadily expanding, prompting the need for new markers to stratify and monitor the cardiovascular risk in oncological patients before, during, and after the completion of treatment. Advanced noninvasive cardiac imaging has raised great interest in the early detection of cardiovascular diseases and cardiotoxicity in oncological patients. Nuclear medicine has long been a pivotal exam to robustly assess and monitor the cardiac function of patients undergoing potentially cardiotoxic chemotherapies. In addition, recent radiotracers have shown great interest in the early detection of cancer treatment-related cardiotoxicity. In this review, we summarize the current and emerging nuclear cardiology tools that can help identify cardiotoxicity and assess the cardiovascular risk in patients undergoing cancer treatments, and discuss the specific role of nuclear cardiology alongside other noninvasive imaging techniques.

show abstract

“…Diarrhea is another frequent side effect in individuals treated with TKIs, but not in those treated with mAbs. Gefitinibrelated interstitial pneumonitis stands as the sole recorded serious hazard linked to these drugs [61]. Erlotinib and gefitinib appear to exhibit a low occurrence of cardiotoxicity when employed solely as inhibitors of ErbB1.…”

Section: Colorectal Tumors and Epidermal Growth Factor Receptor Signa...mentioning

confidence: 99%

Recent Perspectives on Cardiovascular Toxicity Associated with Colorectal Cancer Drug Therapy

Kashyap,

Mangrulkar,

Kushwaha

et al. 2023

Pharmaceuticals

View full text Add to dashboard Cite

Cardiotoxicity is a well-known adverse effect of cancer-related therapy that has a significant influence on patient outcomes and quality of life. The use of antineoplastic drugs to treat colorectal cancers (CRCs) is associated with a number of undesirable side effects including cardiac complications. For both sexes, CRC ranks second and accounts for four out of every ten cancer deaths. According to the reports, almost 39% of patients with colorectal cancer who underwent first-line chemotherapy suffered cardiovascular impairment. Although 5-fluorouracil is still the backbone of chemotherapy regimen for colorectal, gastric, and breast cancers, cardiotoxicity caused by 5-fluorouracil might affect anywhere from 1.5% to 18% of patients. The precise mechanisms underlying cardiotoxicity associated with CRC treatment are complex and may involve the modulation of various signaling pathways crucial for maintaining cardiac health including TKI ErbB2 or NRG-1, VEGF, PDGF, BRAF/Ras/Raf/MEK/ERK, and the PI3/ERK/AMPK/mTOR pathway, resulting in oxidative stress, mitochondrial dysfunction, inflammation, and apoptosis, ultimately damaging cardiac tissue. Thus, the identification and management of cardiotoxicity associated with CRC drug therapy while minimizing the negative impact have become increasingly important. The purpose of this review is to catalog the potential cardiotoxicities caused by anticancer drugs and targeted therapy used to treat colorectal cancer as well as strategies focused on early diagnosing, prevention, and treatment of cardiotoxicity associated with anticancer drugs used in CRC therapy.

show abstract

Nuclear medicine imaging methods of radiation-induced cardiotoxicity

Cited by 9 publications

References 123 publications

Cancer survivorship at heart: a multidisciplinary cardio-oncology roadmap for healthcare professionals

Cancer survivorship at heart: a multidisciplinary cardio-oncology roadmap for healthcare professionals

Tales from the future—nuclear cardio-oncology, from prediction to diagnosis and monitoring

Recent Perspectives on Cardiovascular Toxicity Associated with Colorectal Cancer Drug Therapy

Contact Info

Product

Resources

About